CRGT (cortigent.com) Market Value to Book Value Ratio

The history of the market value significantly exceeding the book value illustrates the potential of the growing neuro-implant sector for restoring vision for Cortigent, Inc. (CRGT). The current value of this metric is . Meanwhile, high innovation expenditures completely absorb cash, eliminating current profits. A team of elite engineers is retained through premium conditions and the mission to save patients' sight.

CRGT - Cortigent Inc Market-to-Book Ratio over the range 07/04/2022 - 10/28/2026

This ratio reflects the premium of the assets' market value over their book value. It helps the investor determine the degree of overvaluation or undervaluation of the issuer relative to industry benchmarks. By analyzing the ratio of the company's market valuation to its book value, one can identify liquidity anomalies. For Cortigent, Inc. (CRGT), this indicator confirms capital stability. Reliable neurostimulator logistics ensure high margins, supporting a fair market multiple.

Direct competitors

BIIB - Market Cap to Net Assets Ratio|NBIX (neurocrine.com) - Market Cap to Book Value Multiple|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited (RGC)|Capitalization to Book Value Ratio Axsome|ACADIA Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Xenon Corp XENE|Market Cap to Net Assets Ratio VKTX (Viking Therapeutics)|supernus.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Catalyst Pharmaceuticals, Inc. (CPRX)|DNLI: Market Value to Book Value|Market Value to Book Value Ratio HRMY|Biohaven Corp (BHVN) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio AMLX|Market Cap to Net Assets Ratio TRVI|Praxis Precision Medicines, Inc. - Market Value to Book Value Ratio|Market-to-Book Ratio AVXL (Anavex)|Market Value to Book Value Ratio CeriBell Corp|PRTA - Market Value to Book Value|Market Cap to Net Assets Ratio Alector Therapeutics ALEC|ANNX - Market Cap to Book Value Multiple|omeros.com - Market Capitalization to Book Value Ratio|Neurogene Inc (NGNE) - Market Capitalization to Book Value|AC Immune Corp - Market Capitalization to Book Value Ratio|Market Value to Equity Ratio Voyager Corp|Neumora Therapeutics - Market Capitalization to Book Value Ratio|Market-to-Book Ratio SCLX (scilexholding.com)|TVGN - Market Value to Book Value Ratio|ACOG - Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Cognition Therapeutics, Inc. CGTX|Inhibikase Pharma (IKT) - Market Cap to Book Value Multiple|Market Cap to Net Assets Ratio Cassava Sciences, Inc. SAVA|Assertio (ASRT) - Market Value to Book Value|COYA: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value VTGN|Market Value to Book Value Ratio Ovid Therapeutics Inc. OVID|Capitalization to Book Value Ratio Acumen Pharmaceuticals, Inc (ABOS)|CervoMed Inc. - Market Capitalization to Book Value Ratio|ATHE - Market Cap to Net Assets Ratio|Market Cap to Net Assets Ratio CLNN (Clene Nanomedicine)|PEPG - Market Capitalization to Book Value|JUNS (Jupiter Neurosciences) - Market Capitalization to Book Value Ratio|RLMD (Relmada Corp) - Market Cap to Net Assets Ratio|ANVS - Market Value to Book Value Ratio|Market Value to Book Value Grace Tx|AIFF: Market Capitalization to Book Value Ratio|Market Value to Equity Ratio anewmeds.com KLTO|Market Cap to Net Assets Ratio NeuroSense Therapeutics Ltd. (NRSN)|Reviva Pharmaceuticals, Inc. - Market Cap to Book Value Multiple|MetaVia, Inc. (MTVA) - Market Value to Book Value Ratio|NRXS - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio HSDT|Market-to-Book Ratio Passage Bio|NEUP (Neuphoria Therapeutics, Inc.) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio NERV|Athira Pharma, Inc. (ATHA) - Market Value to Book Value Ratio|Market Value to Book Value ADXN (addextherapeutics.com)|ALZN: Market Value to Book Value Ratio|Market-to-Book Ratio Cyclerion Therapeutics Inc. CYCN|PTIX: Market Capitalization to Book Value Ratio|KTTA: Market Cap to Net Assets Ratio|Market Value to Book Value Ratio ATXI|BCLI (brainstorm-cell.com) - Market-to-Book Ratio|CARA - Market Value to Book Value Ratio|Market Value to Book Value Chromocell Therapeutics Corp (CHRO)|Market Cap to Net Assets Ratio Eliem Therapeutics|Market Cap to Book Value Multiple intracellulartherapies.com (ITCI)|Market Capitalization to Book Value Ratio LBPH|Market Capitalization to Book Value marinuspharma.com MRNS|Market Capitalization to Book Value Ratio NKGN|NRBO - Market Value to Equity Ratio|Market Capitalization to Book Value Ratio SAGE|SNPX (Synaptogenix, Inc) - Market-to-Book Ratio|Market Value to Book Value Ratio Trevena, Inc. (TRVN)|Capitalization to Book Value Ratio Vigil Neuro (VIGL)|Market Cap to Net Assets Ratio Anew Medical, Inc.|Market Cap to Book Value Multiple Cerevel Therapeutics Inc CERE